Voxilaprevir: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) IUPAC name Tag: nowiki added |
No edit summary |
||
Line 52: | Line 52: | ||
'''Voxilaprevir''' is a [[hepatitis C virus]] (HCV) nonstructural (NS) protein [[NS3 (HCV)|3]]/[[NS4A|4A]] protease inhibitor that is used in combination with [[sofosbuvir]] and [[velpatasvir]]. The combination has the trade name ''Vosevi'' and has received a positive opinion from the European [[Committee for Medicinal Products for Human Use]] in June 2017.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004350/WC500229884.pdf|publisher=[[European Medicines Agency]]|title=Summary of opinion: Vosevi|date=22 June 2017}}</ref> |
'''Voxilaprevir''' is a [[hepatitis C virus]] (HCV) nonstructural (NS) protein [[NS3 (HCV)|3]]/[[NS4A|4A]] protease inhibitor that is used in combination with [[sofosbuvir]] and [[velpatasvir]]. The combination has the trade name ''Vosevi'' and has received a positive opinion from the European [[Committee for Medicinal Products for Human Use]] in June 2017.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004350/WC500229884.pdf|publisher=[[European Medicines Agency]]|title=Summary of opinion: Vosevi|date=22 June 2017}}</ref> |
||
In July 18, 2017, ''Vosevi'' is approved by [[Food and drug administration]].<ref>[https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567467.ht[]</ref> |
|||
==References== |
==References== |
Revision as of 21:36, 18 July 2017
Clinical data | |
---|---|
Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C40H52F4N6O9S |
Molar mass | 868.94 g·mol−1 |
3D model (JSmol) | |
| |
|
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and has received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[1]
In July 18, 2017, Vosevi is approved by Food and drug administration.[2]
References
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
- ^ [